Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Nymox reports promising phase II with NX-1207 for BPH

Sep. 21, 2006

Milestone payment to AnorMED for Fosrenol approval in Germany

Sep. 20, 2006

New therapeutic agents for urological disorders imparted in recent patents

Sep. 15, 2006

Pfizer profiles its novel lead 5-HT/NA reuptake inhibitor

Sep. 13, 2006

Italian researchers present a novel selective muscarinic M3 receptor antagonist

Sep. 12, 2006

Enrollment completed in phase II/III study of MN-001 in interstitial cystitis

Sep. 8, 2006

New agents for urinary incontinence disclosed in recent Norgine patent

Sep. 5, 2006

Novel therapeutic agents for nephrotoxicity developed at Hiroshima University

Sep. 4, 2006

New KCa channel activator a promising strategy for micturition control

Sep. 1, 2006

Gabapentin may be effective in treatment of neurogenic overactive bladder

Aug. 30, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...